A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 2

Recruiting

Conditions: Hidradenitis Suppurativa

Registration Number: NCT06046729

Lead Sponsor: Eli Lilly and Company

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria: - Have a diagnosis of HS for at least 12 months. - Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III. - Have an (abscess plus inflammatory nodule) count of at least 5. - Agree to use topical antiseptics daily. - Had an inadequate response or intolerance to a 28-day course of oral antibiotics. Exclusion Criteria: - Have more than 20 draining fistulae. - Have had surgical treatment for HS in the last 4 weeks before randomization. - Have an active skin disease or condition, that could interfere with the assessment of HS. - Have a current or recent acute, active infection. - Are immunocompromised. - Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)

Secondary Outcome Measures

Name	Time	Method
Mean Change from Baseline in Total Number of Abscesses and Inflammatory Nodules;Mean Change from Baseline in HS-related Average Skin Pain Numerical Rating Scale (NRS);Pharmacokinetics (PK): Plasma Concentrations of Eltrekibart